Pharmaceuticals

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

FDA approves the first generic of a vital nutrition drug, granting Apotex a 180-day exclusive edge and signaling major cost savings for healthcare.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

A new report reveals a major gap in AI adoption as digital disruptors and generic GLP-1s force Canadian pharmacies to innovate or risk being left behind.

European non-profit ELRIG launches its first US conference, a free-to-attend event aiming to connect scientists and tackle intractable drug targets.

As the $525B cold chain market booms and regulations tighten, Circle Logistics is enhancing its services to offer shippers greater reliability and compliance.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

A new alliance aims to deliver nine vital rare disease therapies to Africa, tackling one of global health's most profound access challenges.

ANI Pharmaceuticals launches a generic version of Carbatrol, aiming for a slice of a $65M market and promising improved patient access for chronic conditions.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

Endpoint's new RTSM platform update introduces conversational AI and advanced supply chain tools to give sponsors greater control over complex global trials.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

A landmark study reveals 100% tumor control with a personalized radiation therapy, offering profound new hope for patients with inoperable liver cancer.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.